SCHEMBL1361080

SCHEMBL1361080

C=CCOC(=O)C(C)(CC=C)CC=C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.41
TSHR P16473 3/20 0.39
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPT P10636 3/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
RHOA P61586 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
PKM P14618 1/20 0.33
KDM4E B2RXH2 2/20 0.32
MAPK1 P28482 2/20 0.32
HTT P42858 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
KMT2A Q03164 1/20 0.31
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11012846 0.83 TSHR (0.43) CYP3A4TSHRALDH1A1HSD17B10TDP1
SCHEMBL782365 0.83 TSHR (0.39) CYP3A4TSHRALDH1A1HSD17B10TDP1
SCHEMBL12751316 0.83 PKM (0.41) CYP3A4TSHRALDH1A1HSD17B10PKM
SCHEMBL6050114 0.83 TSHR (0.39) CYP3A4TSHRALDH1A1HSD17B10TDP1
SCHEMBL7866089 0.80 TSHR (0.42) CYP3A4TSHRALDH1A1HSD17B10TDP1
SCHEMBL194466 0.80 TSHR (0.42) CYP3A4TSHRALDH1A1HSD17B10TDP1
SCHEMBL10033540 0.79 TSHR (0.40) CYP3A4TSHRALDH1A1HSD17B10TDP1
SCHEMBL12890738 0.79 TSHR (0.36) CYP3A4TSHRALDH1A1HSD17B10TDP1
SCHEMBL8517677 0.78 TSHR (0.41) CYP3A4TSHRALDH1A1HSD17B10TDP1
SCHEMBL4675516 0.78 TSHR (0.41) CYP3A4TSHRALDH1A1HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227989-A1 Methyl 2,4,9-trithiaadamantane-7-carboxylate UNIVERSITY OF AKRON, THE 2008-09-18 US claimed
EP-1740592-A4 METHYL 2,4,9-TRITHIAADAMANTANE-7-CARBOXYLATE UNIV AKRON (US) 2008-03-26 EP claimed
US-7348441-B2 Methyl 2,4,9-trithiaadamantane-7-carboxylate THE UNIVERSITY OF AKRON (US) 2008-03-25 US claimed
US-20070173650-A1 Methyl 2,4,9-trithiaadamantane-7-carboxylate UNIVERSITY OF AKRON 2007-07-26 US claimed
EP-1740592-A2 METHYL 2,4,9-TRITHIAADAMANTANE-7-CARBOXYLATE THE UNIVERSITY OF AKRON (US) 2007-01-10 EP claimed
WO-2005120186-A2 METHYL 2,4,9-TRITHIAADAMANTANE-7-CARBOXYLATE THE UNIVERSITY OF AKRON (US) 2005-12-22 WO claimed
CN-113614142-A Resin particle, conductive material, and connection structure 积水化学工业株式会社 2021-11-05 CN disclosed
US-8066914-B2 7-ethynyl-2,4,9-trithiaadamantane and related methods UNIVERSITY OF AKRON (US) 2011-11-29 US disclosed
US-20100072425-A1 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS THE UNIVERSITY OF AKRON (US) 2010-03-25 US disclosed
US-7501529-B2 7-Ethynyl-2,4,9-trithiaadamantane and related methods THE UNIVERSITY OF AKRON (US) 2009-03-10 US disclosed
US-20080227989-A1 Methyl 2,4,9-trithiaadamantane-7-carboxylate UNIVERSITY OF AKRON, THE 2008-09-18 US disclosed
US-20080227989-A1 Methyl 2,4,9-trithiaadamantane-7-carboxylate UNIVERSITY OF AKRON, THE 2008-09-18 US disclosed
US-20080177094-A1 7-Ethynyl-2,4,9-Trithiaadamantane and Related Methods AKRON, THE UNIVERSITY OF 2008-07-24 US disclosed
US-20070173650-A1 Methyl 2,4,9-trithiaadamantane-7-carboxylate UNIVERSITY OF AKRON 2007-07-26 US disclosed
US-20070173650-A1 Methyl 2,4,9-trithiaadamantane-7-carboxylate UNIVERSITY OF AKRON 2007-07-26 US disclosed
EP-1740592-A2 METHYL 2,4,9-TRITHIAADAMANTANE-7-CARBOXYLATE THE UNIVERSITY OF AKRON (US) 2007-01-10 EP disclosed
EP-1740592-A2 METHYL 2,4,9-TRITHIAADAMANTANE-7-CARBOXYLATE THE UNIVERSITY OF AKRON (US) 2007-01-10 EP disclosed
WO-2005120186-A2 METHYL 2,4,9-TRITHIAADAMANTANE-7-CARBOXYLATE THE UNIVERSITY OF AKRON (US) 2005-12-22 WO disclosed
WO-2005120186-A2 METHYL 2,4,9-TRITHIAADAMANTANE-7-CARBOXYLATE THE UNIVERSITY OF AKRON (US) 2005-12-22 WO disclosed
WO-2005003089-A2 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS THE UNIVERSITY OF AKRON (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080177094-A1 7-Ethynyl-2,4,9-Trithiaadamantane and Related Methods ALKBH2, TET1, AOX1 CYP3A4 835/4885TSHR 1033/4885ALDH1A1 8/4885
US-20080227989-A1 Methyl 2,4,9-trithiaadamantane-7-carboxylate TST, TPMT, MGMT CYP3A4 2068/4885TSHR 939/4885ALDH1A1 182/4885
US-20100072425-A1 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS ALKBH2, AOX1, TET1 CYP3A4 850/4885TSHR 1027/4885ALDH1A1 12/4885
US-20070173650-A1 Methyl 2,4,9-trithiaadamantane-7-carboxylate TST, TPMT, MGMT CYP3A4 2068/4885TSHR 939/4885ALDH1A1 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.